Oryzon Genomics SA Total Liabilities
Oryzon Genomics SA total liabilities. Based on the latest financial reports, Oryzon Genomics SA (ORY) has total liabilities worth €26.68 Million EUR (≈ $31.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ORY financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Oryzon Genomics SA (2011–2025)
Total liabilities of Oryzon Genomics SA from 2011 to 2025. This chart illustrates how Oryzon Genomics SA's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Oryzon Genomics SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Oryzon Genomics SA Competitors by Total Liabilities
The table below lists competitors of Oryzon Genomics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
D2L Inc
TO:DTOL
|
Canada | CA$157.78 Million |
|
Air Asia Co Ltd
TW:2630
|
Taiwan | NT$2.24 Billion |
|
Armac Locacao Logistica
SA:ARML3
|
Brazil | R$4.39 Billion |
|
Etteplan Oyj
HE:ETTE
|
Finland | €175.43 Million |
|
BAIRONG INC.CL.B -00002
F:6B5
|
Germany | €727.12 Million |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
China | CN¥220.56 Million |
|
Archimedes Tech SPAC Partners II Co. Unit
NASDAQ:ATIIU
|
USA | $8.19 Million |
|
ES Cube Co. Ltd
KQ:050120
|
Korea | ₩16.05 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Oryzon Genomics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ORY total asset value.
Liquidity & Leverage Metrics
Oryzon Genomics SA Total Liabilities Ratios Explained
Oryzon Genomics SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oryzon Genomics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oryzon Genomics SA (2011–2025)
The table below shows the annual total liabilities of Oryzon Genomics SA from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €26.68 Million ≈ $31.19 Million |
+23.07% |
| 2024-12-31 | €21.67 Million ≈ $25.34 Million |
-13.74% |
| 2023-12-31 | €25.13 Million ≈ $29.37 Million |
-19.28% |
| 2022-12-31 | €31.13 Million ≈ $36.39 Million |
+29.04% |
| 2021-12-31 | €24.12 Million ≈ $28.20 Million |
+32.72% |
| 2020-12-31 | €18.18 Million ≈ $21.25 Million |
+22797.11% |
| 2019-12-31 | €79.38K ≈ $92.80K |
-99.64% |
| 2018-12-31 | €22.33 Million ≈ $26.10 Million |
-16.11% |
| 2017-12-31 | €26.61 Million ≈ $31.11 Million |
-1.49% |
| 2016-12-31 | €27.02 Million ≈ $31.58 Million |
+105.63% |
| 2015-12-31 | €13.14 Million ≈ $15.36 Million |
+8.00% |
| 2014-12-31 | €12.16 Million ≈ $14.22 Million |
-13.32% |
| 2013-12-31 | €14.04 Million ≈ $16.41 Million |
+13.63% |
| 2012-12-31 | €12.35 Million ≈ $14.44 Million |
-0.81% |
| 2011-12-31 | €12.45 Million ≈ $14.56 Million |
-- |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more